-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, it was reported that Yasheng Pharmaceutical, a leading company based in China and facing the world, has officially settled in Xuhui, Shanghai with its two major centers of marketing and clinical medicine, and will start the process of commercialization
.
Meanwhile, the Asia-sheng medicine will also carry out strategic cooperation with Shanghai Pharmaceutical Group and the Maple Holdings Limited
.
Among them, Fenglin Group and Fenglin Group will jointly build a collaborative innovation platform in the field of life and health to enhance the original innovation level, and Shanghai Pharmaceutical Holdings Co.
, Ltd.
will carry out in-depth cooperation in the sales of innovative drugs
.
According to data, Yasheng Pharmaceutical was listed on the main board of the Hong Kong Stock Exchange in 2019, and is currently conducting more than 40 clinical trials in China, the United States, Australia and other countries and regions
.
Yasheng Pharmaceuticals stated that the company has successively obtained 12 FDA and 1 EU orphan drug qualifications, and two FDA-reviewed express channel qualifications for new drugs under research
.
It is an innovative drug company with original innovation capabilities and international clinical development capabilities .
On December 18th, the third-generation BCR-ABL TKI oribatinib (trade name: Nerlik) of Ascent Pharmaceuticals was released in the world.
This product is the first third-generation BCR-ABL inhibitor approved for marketing in China.
, Is also a Best-in-class new drug developed by Guangzhou Shunjian Biomedical Technology Co.
, Ltd.
, a wholly-owned subsidiary of Yasheng Pharmaceutical, and has received special support from the national "Major New Drug Creation" project
.
Prior to this, globally, only ponatinib, a third-generation BCR-ABL inhibitor, was approved for listing outside of China
.
In October 2020, Nerlik was included in the priority review by the NMPA New Drug Evaluation Center (CDE) for the treatment of adult patients in the chronic or accelerated phase of CML who are resistant to TKI and accompanied by the T315I mutation; March 2021, This breed was included in the breakthrough treatment breed by CDE
.
In November of this year, Nelek received marketing approval from the National Food and Drug Administration for the treatment of resistance to any tyrosine kinase inhibitor (TKI), and was diagnosed as chronic myeloid leukemia with T315I mutation using a fully validated detection method (CML) Adult patients in the chronic phase (CP) or accelerated phase (AP)
.
Prior to this, Yasheng Pharmaceutical had not yet commercialized its products.
With the launch of Orebatinib, Yasheng Pharmaceutical also officially ushered in the harvest period and entered the commercialization stage
.
For the commercialization of Nellyc, Yasheng Pharmaceuticals continued to make efforts in commercialization cooperation this year, accelerating the layout of strategic cooperation
.
In July this year, Yasheng Pharmaceutical reached 1.
6 billion yuan in strategic cooperation with Cinda Bio, including the joint development and joint promotion of Nelek in the Chinese market.
In November, Yasheng Pharmaceutical signed a strategic cooperation framework with Sinopharm Holdings.
According to the agreement, Yasheng Pharmaceutical will take advantage of Sinopharm’s advantages in channel network, supply chain system and logistics resources.
The two parties will carry out in-depth cooperation in the areas of national channel expansion and maintenance, warehousing and logistics, and market access to promote Nellyke’s acquisition.
The commercialization process after the batch market has enabled Nelek to benefit more patients
.
Now, with the two centers officially settled in Xuhui, Shanghai, it means that the commercialization of Yasheng Pharmaceuticals is further accelerated
.
It is reported that the establishment of the Yasheng Pharmaceutical Marketing and Clinical Medicine Center in Xuhui, Shanghai, will establish cooperation with leading companies in the industry such as Fenglin Group and Shanghai Pharmaceutical Holdings to further build a basis for commercialization
.
The landing of the two centers of Yasheng Pharmaceutical in Xuhui will also further help Xuhui District to accelerate the agglomeration of innovative biotechnology companies and create a highland for original pharmaceutical companies
.
.
Meanwhile, the Asia-sheng medicine will also carry out strategic cooperation with Shanghai Pharmaceutical Group and the Maple Holdings Limited
.
Among them, Fenglin Group and Fenglin Group will jointly build a collaborative innovation platform in the field of life and health to enhance the original innovation level, and Shanghai Pharmaceutical Holdings Co.
, Ltd.
will carry out in-depth cooperation in the sales of innovative drugs
.
According to data, Yasheng Pharmaceutical was listed on the main board of the Hong Kong Stock Exchange in 2019, and is currently conducting more than 40 clinical trials in China, the United States, Australia and other countries and regions
.
Yasheng Pharmaceuticals stated that the company has successively obtained 12 FDA and 1 EU orphan drug qualifications, and two FDA-reviewed express channel qualifications for new drugs under research
.
It is an innovative drug company with original innovation capabilities and international clinical development capabilities .
On December 18th, the third-generation BCR-ABL TKI oribatinib (trade name: Nerlik) of Ascent Pharmaceuticals was released in the world.
This product is the first third-generation BCR-ABL inhibitor approved for marketing in China.
, Is also a Best-in-class new drug developed by Guangzhou Shunjian Biomedical Technology Co.
, Ltd.
, a wholly-owned subsidiary of Yasheng Pharmaceutical, and has received special support from the national "Major New Drug Creation" project
.
Prior to this, globally, only ponatinib, a third-generation BCR-ABL inhibitor, was approved for listing outside of China
.
In October 2020, Nerlik was included in the priority review by the NMPA New Drug Evaluation Center (CDE) for the treatment of adult patients in the chronic or accelerated phase of CML who are resistant to TKI and accompanied by the T315I mutation; March 2021, This breed was included in the breakthrough treatment breed by CDE
.
In November of this year, Nelek received marketing approval from the National Food and Drug Administration for the treatment of resistance to any tyrosine kinase inhibitor (TKI), and was diagnosed as chronic myeloid leukemia with T315I mutation using a fully validated detection method (CML) Adult patients in the chronic phase (CP) or accelerated phase (AP)
.
Prior to this, Yasheng Pharmaceutical had not yet commercialized its products.
With the launch of Orebatinib, Yasheng Pharmaceutical also officially ushered in the harvest period and entered the commercialization stage
.
For the commercialization of Nellyc, Yasheng Pharmaceuticals continued to make efforts in commercialization cooperation this year, accelerating the layout of strategic cooperation
.
In July this year, Yasheng Pharmaceutical reached 1.
6 billion yuan in strategic cooperation with Cinda Bio, including the joint development and joint promotion of Nelek in the Chinese market.
In November, Yasheng Pharmaceutical signed a strategic cooperation framework with Sinopharm Holdings.
According to the agreement, Yasheng Pharmaceutical will take advantage of Sinopharm’s advantages in channel network, supply chain system and logistics resources.
The two parties will carry out in-depth cooperation in the areas of national channel expansion and maintenance, warehousing and logistics, and market access to promote Nellyke’s acquisition.
The commercialization process after the batch market has enabled Nelek to benefit more patients
.
Now, with the two centers officially settled in Xuhui, Shanghai, it means that the commercialization of Yasheng Pharmaceuticals is further accelerated
.
It is reported that the establishment of the Yasheng Pharmaceutical Marketing and Clinical Medicine Center in Xuhui, Shanghai, will establish cooperation with leading companies in the industry such as Fenglin Group and Shanghai Pharmaceutical Holdings to further build a basis for commercialization
.
The landing of the two centers of Yasheng Pharmaceutical in Xuhui will also further help Xuhui District to accelerate the agglomeration of innovative biotechnology companies and create a highland for original pharmaceutical companies
.
